Survodutide: Glucagon/GLP-1 Dual Agonist Research

Abstract still life: two overlapping circles of tinted glass, amber and ink green, casting a combined shadow — **Survodutide.** Illustration, not a product photo.

Research compound. Not approved by FDA Philippines for human use unless stated. Nothing here is a dosing recommendation or medical advice.

What it is

Survodutide is a weekly injectable peptide developed by Boehringer Ingelheim, originally licensed from Zealand Pharma. It activates two receptors at once: the GLP-1 receptor, like semaglutide, and the glucagon receptor. Its development code is BI 456906.

It is being developed for two conditions: obesity, in the SYNCHRONIZE phase 3 programme, and metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), in the LIVERAGE phase 3 trials. The liver is where it may end up most distinct from the drugs already on the market.

How it works

The GLP-1 half does the familiar work: slower stomach emptying, glucose-dependent insulin release and reduced appetite.

The glucagon half is the unusual part. Glucagon normally raises blood sugar, which sounds like the wrong thing for a metabolic drug. But glucagon receptor activation also increases energy expenditure and pushes the liver to burn fat rather than store it. The GLP-1 component counters the blood-sugar rise. The design bet is that combining the two gives weight loss plus a direct effect on liver fat that appetite suppression alone does not.

The same logic sits behind mazdutide, another glucagon/GLP-1 dual agonist, and behind the glucagon arm of the triple agonist retatrutide.

What the research found

Obesity: SYNCHRONIZE-1

The first phase 3 result, published in NEJM in June 2026, enrolled 725 adults with obesity and no diabetes for 76 weeks. Counting everyone randomised, mean weight loss was:

12.2% on 3.6 mg
13.0% on 6.0 mg
5.4% on placebo

Boehringer's topline release, which analysed people who stayed on treatment, reported up to 16.6% weight loss versus 3.2% on placebo, and 85.1% of treated participants reaching at least 5% loss versus 38.8% on placebo. Boehringer said the weight lost was mainly fat tissue. The programme also includes SYNCHRONIZE-2, in adults with obesity and type 2 diabetes.

These numbers put survodutide below tirzepatide and retatrutide in their own trials. Its case rests less on the scale and more on the liver.

Liver: phase 2 MASH trial

Sanyal and colleagues (NEJM, 2024) randomised 293 adults with biopsy-confirmed MASH and liver fibrosis to 2.4, 4.8 or 6.0 mg weekly or placebo for 48 weeks. Improvement in MASH without worsening of fibrosis, the standard regulatory endpoint, occurred in 47%, 62% and 43% of the three dose groups versus 14% on placebo. Fibrosis improved by at least one stage in 34%, 36% and 34% versus 22% on placebo.

Boehringer lists a US FDA Breakthrough Therapy designation from September 2024, and the drug is now being tested in the LIVERAGE trial (about 1,800 participants) and LIVERAGE-Cirrhosis (about 1,590), which will measure whether it changes liver outcomes over the long term.

Side effects reported in studies

Gastrointestinal effects were very common. In SYNCHRONIZE-1, GI symptoms were reported by 80.9% to 89.7% of participants on survodutide versus 47.9% on placebo, mostly mild to moderate. Boehringer noted that discontinuations clustered during dose escalation. No deaths occurred in the trial.

In the phase 2 MASH trial, nausea (66% versus 23% on placebo), diarrhoea (49% versus 23%) and vomiting (41% versus 4%) were the leading events. See side effect management.

Survodutide vs other multi-receptor agonists

Compound	Receptors	Developer	Stage (Sep 2026)
Survodutide	Glucagon + GLP-1	Boehringer Ingelheim / Zealand	Phase 3
Mazdutide	Glucagon + GLP-1	Innovent / Lilly	See its page
Tirzepatide	GIP + GLP-1	Lilly	Approved
Retatrutide	GIP + GLP-1 + glucagon	Lilly	Phase 3, US filing planned Q1 2027
CagriSema	Amylin + GLP-1	Novo Nordisk	Filed with US FDA

Status in the Philippines

Survodutide is an investigational drug. It is not approved in any country and is not registered with FDA Philippines, so it cannot be sold here as a medicine. What appears on research-chemical lists under the name has no connection to Boehringer's manufacturing and no way to confirm it matches the trial molecule.

People in the Philippines looking at a glucagon-based drug for fatty liver should know that the evidence is still phase 2 for liver outcomes. MASH diagnosis and monitoring need imaging or biopsy and liver enzymes; see bloodwork in the Philippines. Registered GLP-1 medicines are available here, and prescribing belongs with a licensed Philippine physician.

Storage

There is no approved label. Research handling follows other GLP-1 peptides: lyophilised powder refrigerated, reconstituted solution at 2 to 8°C, never frozen, kept out of heat. In the Philippine climate that means a plan for brownouts and ice packs for any transport.

Doses used in published research

What investigators actually administered, as reported in the cited study. This is a record of the literature, not a recommendation.

Study	Population	Regimen
SYNCHRONIZE-1, le Roux et al., NEJM 2026	725 adults with obesity (BMI 30 or more, or 27 or more with complications), without diabetes	3.6 mg or 6.0 mg subcutaneous once weekly, 76 weeks
Sanyal et al., NEJM 2024 (phase 2)	293 adults with biopsy-confirmed MASH and liver fibrosis	2.4, 4.8 or 6.0 mg subcutaneous once weekly, 48 weeks (24 weeks escalation, 24 weeks maintenance)

Common questions

How much weight did people lose on survodutide?

In SYNCHRONIZE-1, adults without diabetes lost a mean 13.0% of body weight on 6.0 mg and 12.2% on 3.6 mg at 76 weeks, versus 5.4% on placebo. Among those who stayed on treatment, Boehringer reported up to 16.6% versus 3.2%.

How is survodutide different from semaglutide?

Semaglutide acts only on the GLP-1 receptor. Survodutide also activates the glucagon receptor, which is expected to raise energy expenditure and act directly on the liver. That liver effect is why it is being tested in MASH.

Is survodutide approved?

No. It is in phase 3 and no country had approved it as of September 2026. It is not registered with FDA Philippines.

What are the side effects of survodutide?

Mostly gastrointestinal. In SYNCHRONIZE-1, GI symptoms were reported by 80.9% to 89.7% of people on survodutide versus 47.9% on placebo, mostly mild to moderate.

Is survodutide the same as mazdutide?

No. Both combine glucagon and GLP-1 activity, but they are different molecules from different companies. Survodutide comes from Boehringer Ingelheim and Zealand Pharma; mazdutide from a different developer.